Subscribe to Email Alerts
Menu
About Us
About INOVIQ
Market Opportunity
Board
Management
Medical & Scientific Advisory Board
Partners
Distributors
Compliance
Careers
Technology
Our Science
NETs Platform
SubB2M Platform
BARD1 Biomarker Technology
hTERT ICC Assay
Intellectual Property
Publications
Resources
Business Development
Products
Our Products
EXO-NET® Pan-Exosome
Product Overview
Technical Information
Data & Figures
Ordering
hTERT ICC Test
Pipeline
Development Pipeline
NeuCA15-3 Test
NeuCA125 Test
EXO-Ovarian Cancer Test
Exosome Therapeutics
Investors
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
News & Events
INOVIQ in the News
Conferences & Events
Contact
Contact Us
Subscribe to Email Alerts
ASX Announcements
Heading &
Sub-heading can be edited through HQI
Investors
>
ASX Announcements
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
6-Apr-2022
Updated Investor Presentation
6-Apr-2022
SubB2M Paper Published in BMC Cancer Journal
5-Apr-2022
INOVIQ Engages ResearchDX to Develop & Validate SubB2M-Tests
1-Apr-2022
INOVIQ & UQ Collaborate on Exosome-based Ovarian Cancer Test
28-Mar-2022
Update on Legal Proceedings and BARD1 Autoantibody Program
25-Feb-2022
Appendix 4D and Half Year Financial Report
23-Feb-2022
Brazilian Patent Issued for Lung & Colorectal Cancer
3-Feb-2022
Updated Investor Presentation
31-Jan-2022
Notification regarding unquoted securities - IIQ
31-Jan-2022
Appendix 4C & Quarterly Activities Report
Previous
1
2
3
4
5
6
Next